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ABSTRACT
ObjeCtive
To forecast dementia prevalence with a dynamic 
modelling approach that integrates calendar trends 
in dementia incidence with those for mortality and 
cardiovascular disease.
Design
Modelling study.
setting
General adult population of England and Wales.
PartiCiPants
The English Longitudinal Study of Ageing (ELSA) is a 
representative panel study with six waves of data across 
2002-13. Men and women aged 50 or more years, selected 
randomly, and their cohabiting partners were recruited to 
the first wave of ELSA (2002-03). 11392 adults participated 
(response rate 67%). To maintain representativeness, 
refreshment participants were recruited to the study at 
subsequent waves. The total analytical sample 
constituted 17 906 people. Constant objective criteria 
based on cognitive and functional impairment were used 
to ascertain dementia cases at each wave.
Main OutCOMe Measures
To estimate calendar trends in dementia incidence, 
correcting for bias due to loss to follow-up of study 
participants, a joint model of longitudinal and 
time-to-event data was fitted to ELSA data. To forecast 
future dementia prevalence, the probabilistic Markov 
model IMPACT-BAM (IMPACT-Better Ageing Model) was 
developed. IMPACT-BAM models transitions of the 
population aged 35 or more years through states of 
cardiovascular disease, cognitive and functional 
impairment, and dementia, to death. It enables 
prediction of dementia prevalence while accounting 
for the growing pool of susceptible people as a result 
of increased life expectancy and the competing effects 
due to changes in mortality, and incidence of 
cardiovascular disease.
results
In ELSA, dementia incidence was estimated at 14.3 per 
1000 person years in men and 17.0/1000 person years 
in women aged 50 or more in 2010. Dementia incidence 
declined at a relative rate of 2.7% (95% confidence 
interval 2.4% to 2.9%) for each year during 2002-13. 
Using IMPACT-BAM, we estimated there were 
approximately 767 000 (95% uncertainty interval 
735 000 to 797 000) people with dementia in England 
and Wales in 2016. Despite the decrease in incidence 
and age specific prevalence, the number of people with 
dementia is projected to increase to 872 000, 1 092 000, 
and 1 205 000 in 2020, 2030, and 2040, respectively. 
A sensitivity analysis without the incidence decline 
gave a much larger projected growth, of more than 
1.9 million people with dementia in 2040.
COnClusiOns
Age specific dementia incidence is declining. The 
number of people with dementia in England and Wales 
is likely to increase by 57% from 2016 to 2040. This 
increase is mainly driven by improved life expectancy.
Introduction
It has been predicted that by 2050 well in excess of 100 
million people worldwide will have dementia.1  Current 
costs of dementia to the UK economy are estimated at 
£23bn ($29bn; €26bn) annually.2  Burden of disability 
and years of life lost due to dementia in the UK 
increased by 76% between 1990 and 2010.3 Accurate 
projections for burden of dementia is a key step for 
planning to meet future needs.
Projections of dementia burden based on constant 
prevalence or incidence rates may not be precise,4-6  as 
they will only reflect population aging. Accurate predic-
tions rely on accounting for changes in dementia inci-
dence as well as changes in mortality rates. The 
competing effect of cardiovascular risk on future pro-
jections of dementia is also important. Alzheimer’s dis-
ease, vascular dementia, and cardiovascular disease 
share risk factors.7 8  Thus, vascular risk reduction is 
likely to drive down age specific dementia incidence 
while, in contrast, leading to increased life expectancy 
and larger numbers susceptible to dementia.9  Given the 
opposing effects, simultaneous modelling of cardiovas-
cular disease, dementia, and mortality is likely to 
enhance the accuracy of projections. Addressing shared 
determinants of disease follow recommendations from 
the National Institute for Health and Care Excellence,10 
WhAT IS AlReAdy knoWn on ThIS TopIC
Alzheimer’s Society UK predicts if age specific prevalence of dementia remains 
constant, there will be over 1.7 million people with dementia in the UK by 2050
Studies in England, the Netherlands, and United States have shown a decline in 
dementia incidence over time
WhAT ThIS STudy AddS
The decline in dementia incidence each year in 2002-13 was steeper than that 
observed in previous studies
The Markov model shows that despite a decline in age specific dementia incidence, 
overall prevalence of this condition is rising; however, the increase is not as large 
as predicted by simple projections of prevalence into the future
This study estimates that by 2040 in England and Wales there will be more than 
1.2 million people with dementia, an increase of 57% from 2016
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Public Health England, and the World Health Organiza-
tion in the Blackfriars consensus.11  Such modelling 
approaches are, however, currently lacking.4
A key determinant of the future burden of dementia 
will be the underlying incidence trend. Although the 
balance of evidence suggests dementia incidence is 
declining,12-18  the magnitude of the decline is less cer-
tain. The ideal approach to determine time trends in 
dementia incidence would be based on continuous 
monitoring of a defined and representative population 
using a standard approach for case identification.13 19 20 
In large epidemiological studies, changes in clinical 
 criteria21 22  and poor diagnostic agreement among clini-
cians23  are sources of variation in measured dementia 
incidence over time. Another challenge in establishing 
time trends is higher dropout among cohort study par-
ticipants affected by, or in the preclinical stages of, 
dementia,24 25 which leads to inaccurate estimates of 
dementia incidence and calendar trends.
In the present study, we developed a novel probabi-
listic Markov method (IMPACT-Better Ageing Model) to 
simultaneously model the transitions of the population 
through states of health, cardiovascular disease, cogni-
tive and functional impairment, and dementia, to 
death, to obtain projections for the prevalence of 
dementia in England and Wales up to 2040. To account 
for the effect of selective dropout of study participants 
and to obtain unbiased estimates for dementia inci-
dence over the past 15 years, with which to inform the 
model, we applied a robust joint modelling technique26 
to data from the English Longitudinal Study of Ageing.
Methods
Study population and sample
The English Longitudinal Study of Ageing (ELSA) sam-
ple was recruited in 2002-03 from participants of the 
1998-2001 health surveys for England.27 28  The sample 
was drawn by postcode sector, stratified by health 
authority and proportion of households in non-manual 
socioeconomic groups. A total of 12 099 men and 
women participated (response rate 67%), including 
11 392 people aged 50 or more selected through the ran-
dom sampling and 707 cohabiting partners. Survey 
weights were applied to ensure study participants 
formed a representative sample. Comparison of socio-
demographic characteristics against national census 
indicated the ELSA sample was broadly representative 
of the population of England.27 To maintain representa-
tiveness of the study sample, refreshment participants 
were recruited to the study at wave 3 (2006-07; ages 
50-55), wave 4 (2008-09; ages 50-74), and wave 6 (2012-
13; ages 50-55) all drawn from the health surveys of 
England for the preceding years. A total of 17 906 
 participants were recruited to the study between waves 
1 and 6 (see supplementary figure 1). Wave 7 data (2014-
15) was not included in the analysis other than to iden-
tify transient impairments in cognition or function. At 
each wave, participants were interviewed to collect 
extensive demographic, medical, and lifestyle data. 
Clinical examinations were conducted at waves 2, 4, 
and 6. Participants provided written informed consent.
assessment of cognitive function in elsa
Three sets of cognitive function tests were administered 
at every wave of ELSA. These tests, and method of being 
administered, include orientation to time, day, month, 
and year; immediate and delayed memory: one noun 
from a list of 10 is presented every two seconds to the 
participant who is then asked to recall as many words 
as possible immediately and after a short delay; and 
verbal fluency: participants are asked to name as many 
animals as possible in one minute. At waves 1, 4, and 6 
a test of numeracy function was carried out by asking 
participants to solve four simple mathematics prob-
lems. At wave 6 an additional test of literacy was carried 
out by asking participants to deduce from a medicine 
label the number of days the medicine should be taken. 
Orientation to time was used to assess concentration, 
scores on the immediate and delayed recall were used 
as a measure of memory function, and scores on the 
animal naming, literacy, and numeracy test were used 
to measure verbal fluency and executive function.
The short version of the informant questionnaire for 
cognitive decline (IQCODE) was administered for partic-
ipants unable to take part in the study who provided 
consent in advance or through a consultee.29  The 
IQCODE comprises 16 questions asking a proxy infor-
mant (usually an immediate family member) how the 
participant’s state of memory, ability to learn new tasks, 
judgment, and handling of key everyday situations (eg, 
making decisions on every day matters, or handling 
money for shopping) are compared with two years ago. 
The answers are graded on 5 point scales, from much 
improved to much worse. Use of the IQCODE question-
naire to identify cognitive impairment has been previ-
ously validated.29 The participant or proxy informants 
were asked about any doctor diagnosis of dementia.
assessment of functional impairment
Participants or proxy informants were asked about the 
ability of the participant to independently conduct 
basic activities of daily living. Such activities are key 
tasks related to self care and consist of getting in or out 
of bed, walking across a room, bathing or showering, 
using the toilet, dressing, cutting food, and eating. 
Impairment in independently performing one or more 
activities of daily living was defined as functional 
impairment. We considered impairment in conducting 
activities of daily living reported once, where the partic-
ipant fully recovered at all further waves of data collec-
tion, to be transient and did not categorise those as 
functional impairment. Transient impairments at wave 
6 were identified using wave 7 data.
Case definition of cognitive impairment and dementia
We used an operational criteria based on cognitive func-
tion tests and IQCODE to define cognitive impairment.
Cognitive function tests—we used the criteria adapted 
for cognitive impairment no dementia (CIND).19 30 Cog-
nitive impairment was defined as impairment in two or 
more domains of cognitive function. Impairment in 
each domain of cognitive function is defined as a score 
of 1.5 standard deviations below the mean or lower 
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compared with the population aged 50-80 years with 
the same level of education. Education was categorised 
in three levels: no qualification; O-level, A-level, or 
equivalent; and higher (university) education. We did 
not find considerable differences between men and 
women in the distribution of cognitive function scores 
after adjustment for age and education. We did not find 
evidence of large learning effects in consecutive cogni-
tive function tests. The annual age specific and sex spe-
cific decline observed among participants who 
conducted the tests four or more years apart was similar 
to participants who conducted the tests two years apart. 
The cognitive assessment was considered invalid if the 
participant had responded to fewer than three tests on 
the cognitive battery. To avoid the effect of transient 
cognitive decline, resulting from delirium or other men-
tal disorders, if the participant improved by 1 SD or 
more on cognitive tests at the consecutive wave, they 
were considered to not have cognitive impairment. 
Transient impairments of cognition at wave 6 were 
identified through cognitive assessment at wave 7.
IQCODE—a cut point of 3.3-3.6 is used for identifica-
tion of cognitive impairment based on the IQCODE.29 
We used a conservative cut-point of 3.6 for specificity.
Dementia caseness was defined either as a combina-
tion of cognitive impairment (according to the previously 
described definitions) and functional impairment (diffi-
culty in performing one or more activities of daily living), 
or self reported doctor diagnosis of dementia. The opera-
tional definition adapted in this study conforms to crite-
ria from the Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition, for diagnosis of dementia (see 
supplementary file, section 1, for explanation).
Cardiovascular disease and mortality
Cardiovascular disease in ELSA was ascertained by self 
reported doctor diagnosis of myocardial infarction, 
stroke, angina, coronary artery bypass grafting, or 
death from cardiovascular causes. Incidence of cardio-
vascular disease was defined as a first ever record of 
disease or intervention for each participant. Date and 
cause of death for ELSA study participants are obtained 
by data linkage with the UK Office for National 
 Statistics.
statistical analysis
Trends in dementia incidence
We estimated the calendar trend in age specific demen-
tia incidence across 2002-13 in ELSA in three statistical 
models with increasing complexity. Firstly, we esti-
mated the calendar trend by fitting a Cox proportional 
hazards regression with incident dementia as the out-
come and terms for age, age squared, sex, interactions 
of age and sex, and calendar time. Date of dementia was 
the mid-point between the wave in which dementia was 
reported or ascertained and the latest previous assess-
ment. For participants who would only be classified as 
having dementia if they had impairment in numeracy 
function (assessed at waves 1, 4, and 6), the date of 
ascertainment was the mid-point between the two 
 consecutive assessments that included the numeracy 
function test. The Cox proportional hazards analysis 
does not correct for bias as a result of selective dropout 
or the competing effect of mortality.
In the second stage, we fitted a competing risks 
model31 32 with incident dementia as the outcome and 
mortality as a competing risk. Unlike a Cox proportional 
hazards model, in competing risks analysis, partici-
pants who die are not censored uninformatively and the 
effect of change in mortality over time on calendar 
trends in dementia incidence is accounted for.
At the third stage, to account for non-random drop-
out as well as competing risks of mortality, we fitted a 
joint model of longitudinal and time to event data.26 
The longitudinal outcome of the joint model was the 
average standardised cognitive function test score, and 
the survival outcome was incident dementia. The sur-
vival outcome (incident dementia) was dependent on 
both the current value and the slope of the trajectory of 
the longitudinal outcome (standardised score on cogni-
tive function tests). Other independent covariates in the 
model were age at entry, age squared, time since entry 
in the study (representing the effect of aging), time 
squared, sex, calendar year, level of education, and 
midlife history of obesity, hypertension, and diabetes. 
The longitudinal component allowed random inter-
cepts and random slopes for the effect of age at entry 
and time since entry to the study. From the joint model 
we obtained individual level predictions for probability 
of dementia for ELSA study participants who were alive, 
including those lost to follow-up. To obtain calendar 
trends in incidence of dementia, we fitted linear regres-
sion models with log odds of incident dementia as the 
outcome to the data with terms for sex, age, age 
squared, interaction of sex with age and with age 
squared, and calendar time. The validity of this method 
to obtain predictions of incident dementia was assessed 
by comparing joint model predictions for future waves 
with data driven observed incidence rates. We validated 
the dementia case definition by comparing age specific 
incidence rates with those obtained from the Cognitive 
Function and Ageing Study-II.13
We examined the effect of changes in potential vascu-
lar and lifestyle risk factors on calendar trends in 
dementia incidence by entering risk factors as time 
varying covariates in regression models, with log odds 
of dementia as the outcome. The method for assess-
ment of risk factors is shown in section 1 of the supple-
mentary material.
Trends in dementia prevalence—IMPACT-BAM
To obtain valid projections for dementia prevalence to 
2040, we developed IMPACT-BAM (fig 1), a probabilistic 
discrete time Markov model. IMPACT-BAM models tran-
sitions of the England and Wales population aged 35 or 
more years through states of illness and mortality. The 
model is initially populated using age-sex specific preva-
lence estimates, with transition probabilities applied at 
each one year iteration to predict number of deaths and 
prevalence of each of the eight states of IMPACT-BAM at 
the next calendar year. The model predicts future preva-
lence of cardiovascular disease, dementia, and 
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 functional impairment in addition to life expectancy, dis-
abled and disability-free life expectancy, and mortality.
Input data to inform IMPACT-BAM include the popu-
lation structure, the age-sex specific initial prevalence 
of each health state in the model, and age-sex-calendar 
time specific transition probabilities between states.
We obtained the numbers of the population in 
England and Wales in each stratum of age and sex at 
year 2006 (the start of the IMPACT-BAM model itera-
tions) from ONS. Numbers of men and women who 
reach age 35 and enter the model at each calendar year 
are also obtained from ONS predictions. The entering 
cohort of 35 year olds is assumed to be free of cardiovas-
cular disease and cognitive and functional impairment.
The baseline age and sex specific prevalence of each 
health state of the model was calculated using six waves 
of ELSA data pooled together and attributed to mid-point 
of the data collection timeframe, in 2006. The values 
obtained from this method corresponded to values 
observed at wave three (2006-08; see supplementary fig-
ure 2). We then used the curve fitting tool in MATLAB to 
obtain data for single year of age, starting at age 35 years.
The age-sex specific probability of transition from 
statei to statej in IMPACT-BAM (transition probability 
(TPij)) for 2006 was obtained by fitting a logistic regres-
sion model on ELSA data with statej as outcome and 
terms for age, sex, interaction of age and sex, and a vari-
able defining the initial state (statei). Transition proba-
bilities to CIND (states 3 and 4 in figure 1) additionally 
included terms for age squared and its interaction with 
sex. We pooled transitions from wave n to wave n+1 in 
ELSA so that each individual contributed as many 
observations as corresponded to the number of two year 
epochs in which they participated in the study until 
being censored. We used a logistic model rather than a 
Cox proportional hazards model because the two years 
between data collection waves were relatively constant 
between participants and over time, and, unlike hazard 
ratios, odds ratios can be transformed into transition 
probabilities. Margins of the model provide two year 
transition probabilities for each stratum of sex, and sin-
gle year of age at 2006. The two year probability (P) was 
then translated into one year transition probability 
using the formula: TP=1−exp((ln(1−P))/2)
All transition probabilities entered in IMPACT-BAM 
are calendar time specific. We calculated probabilities of 
cardiovascular and non-cardiovascular mortality up to 
2040 in five year age bands using the Bayesian Age 
Period Cohort (BAPC) model with ONS mortality and 
population estimates from 1982-2012 for England and 
Wales as inputs (see supplementary figure 3).33 Mortality 
rates from each health state were assumed to change in 
parallel with overall cardiovascular and non- 
cardiovascular mortality rates. We calculated health 
state specific transition probabilities to cardiovascular 
and non-cardiovascular mortality by estimating the 
odds ratios of death from each health state using ELSA 
data (see supplementary table 1) and using the odds 
ratios to obtain the probability of deaths from cardiovas-
cular and non-cardiovascular causes from each health 
state compared with that in the general population. To 
obtain state specific cardiovascular and non-cardiovas-
cular mortality rates we applied the probability ratios to 
overall cardiovascular and non-cardiovascular mortal-
ity rates shown in supplementary figure 3. The decline in 
cardiovascular incidence paralleled the decline in 
Non-cardiovascular disease death (10)Cardiovascular disease death (9)
Disease-free population (1)
Non-cardiovascular
disease, non-
dementia functional
impairment (8)
Cardiovascular
disease and
functional
impairment (5)
Cardiovascular
disease (2)
Cognitive
impairment (4)
Cardiovascular
disease and cognitive
impairment (3)
Cardiovascular
disease and cognitive
and functional
impairment
(dementia) (6)
Cognitive and
functional
impairment
(dementia) (7)
Population
vector
Fig 1 | iMPaCt-better ageing Model (iMPaCt-baM). numbers represent different health states and mortality. Population 
vector represents the number of men and women reaching age 35 and entering the model at each calendar year. states 6 
and 7 represent dementia. states 5, 6, 7, and 8 represent functional impairment or disability
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table 1 | summary of assumptions underlying the iMPaCt-baM model
assumption justification
IMPACT-BAM models health transitions in the population of England and Wales aged 35 or more through to death. The input data for the probabilistic Markov model are the 
population size in each age and sex stratum, initial health state prevalence values, and transition probabilities by age, sex, and calendar year
Population numbers by age and sex
Estimates for population numbers by sex and five year age groups at 
model baseline were obtained from the UK Office for National 
Statistics (ONS). At each one calendar year iteration of the model, 
men and women reaching age 35 were entered. The predictions for 
number of people aged 35 by year were obtained from ONS
Assumption 1: ONS predictions are realistic
Assumption 2: migration is not a major source of bias
ONS provides official estimates for population demographics
starting prevalence values
Initial prevalence of health states in the model by age and sex were 
obtained from the English Longitudinal Study of Ageing (ELSA)
Assumption 3: ELSA is a representative sample of the population of 
England and Wales
Accuracy of prevalence values depends on how well ELSA represents the population of England and Wales. 
ELSA study participants aged 50 or more were selected at random. The core participant’s cohabiting 
partners, including adults aged less than 50, were also enrolled in the study. The overall response rate was 
67%. To ensure study participants form a representative sample, survey weights are applied. To maintain 
representativeness at every phase of data collection, refreshment samples are recruited to the study 
periodically. Comparisons of the sociodemographic characteristics of participants against results from the 
national census indicated that the ELSA sample was broadly representative of the English population
To improve statistical power, six waves of ELSA data were pooled. 
Prevalence estimates of cardiovascular disease and cognitive and 
functional impairment that define the health states were obtained 
from pooled data and attributed to 2006, which is the mid-point of 
the ELSA data collection timeframe and the baseline of the model
Assumption 4: Prevalence estimates from six pooled waves of data 
provide a precise and accurate estimate of prevalence at mid-point 
of the data collection timeframe
The prevalence values obtained from the pooled ELSA data matched the prevalence values obtained at 
the mid-point (2006, wave 3). Estimates for prevalence of cardiovascular disease are displayed as an 
example in supplementary figure 2
Assumption 5: The prevalence of each health state at each calendar year 
from the starting point (2006) onwards, equals the number of people who 
were in that health state in the previous year, plus new incident cases, 
minus those who made the transition to another health state or died from 
any cause. Number of new incident cases and numbers of death were 
determined by transition probabilities to and from that condition
Epidemiological concept applied to Markov models
transition probabilities
Transition probabilities were obtained as a function of age and sex 
from incident cases between wave n and n+1 in ELSA. As with 
estimates of prevalence values, the transition probabilities obtained 
from pooling ELSA epochs were attributed to the mid-point of the 
data collection period
Assumption 6: Transition probabilities, (equivalent to incidence by 
age, sex, or calendar year) for cardiovascular disease, dementia, 
functional impairment, and mortality in ELSA are similar to those for 
England and Wales
Incidence of cardiovascular disease and dementia by age and sex were consistent with age, and sex 
specific incidence values obtained from independent external sources for the corresponding calendar 
time
Estimates of dementia incidence were available from the Cognitive Function and Ageing Study II (CFAS 
II, 2008-11). Incidence of dementia in the corresponding timeframe is compatible with CFAS-II 
estimates (see supplementary figure 5).
Deaths predicted by IMPACT-BAM matched with observed and predicted mortality rates from the ONS 
(see supplementary figure 13)
Assumption 7: Transition probabilities are equivalent to a weighted 
average across the spectrum of the severity of each condition, thus 
varying severities among people in each health state is accounted 
for. Similarly, survival of those with each condition is assumed to be 
equivalent to the weighted average of survival of people with 
different levels of severity
Modelling is based on a single transition probability for each age, sex, and calendar year stratum and health 
transition. The probability of death or development of functional impairment among those with cardiovascular 
disease or cognitive impairment is dependent on the severity of cardiovascular disease or cognitive 
impairment. Under the assumption that ELSA participants are a representative sample of the population, the 
spectrum of the severity of conditions (eg, cardiovascular disease, or cognitive impairment) observed in ELSA 
is proportionate to that at population level. As such, transition probabilities obtained from ELSA are a weighted 
average of the transition probabilities across the spectrum of the severity of the conditions
The weighted average transition probability multiplied by the total number of people in a health state 
is mathematically equivalent to the sum of the product of severity specific transition probabilities and 
severity specific numbers of people in that health state
Assumption 8: The effects of comorbidity (such as diabetes) are 
accounted for in the model
Since ELSA participants are assumed to be a representative sample of the population of England after 
weighting (see above), estimates for risks of dementia, cardiovascular disease, functional impairment 
and death obtained from ELSA reasonably represent a weighted average of risk levels across the 
spectrum of the severity of these conditions and comorbidities
Calendar trends 
Transition probabilities (mortality rates and incidence of cardiovascular disease and dementia) change over time
Assumption 9: The observed downward calendar trend in mortality 
rates over the past two decades will continue to the future
Data obtained from ONS show that cardiovascular and non-cardiovascular mortality rates followed 
steady and linear downward trends over the past two decades. We assumed the most likely scenario 
would be that these trends will continue (see supplementary figure 3)
Assumption 10: Life expectancy and maximum lifespan are 
amenable to being increased
Changes in life expectancy are accounted for by application of mortality rates. As mortality rates 
continue to decline, life expectancy will increase
Assumption 11: Trends in incidence of cardiovascular disease over 
time are parallel to cardiovascular mortality
Age and sex standardised cardiovascular incidence and mortality rates declined in parallel in ELSA 
(see supplementary figure 4).
To examine the uncertainty of this assumption, we conducted a sensitivity analysis assuming incidence 
of cardiovascular disease does not decline any further (results shown in supplementary figure 16)
Assumption 12: Dementia incidence declines over time A decline in dementia incidence has been reported in studies in England, the Netherlands, and USA. 
The magnitude of the calendar trend in England and Wales is less certain. We determined the calendar 
trend corrected for deaths and loss to follow-up of study participants, utilising a robust statistical 
technique to model ELSA data
We conducted sensitivity analyses with calendar trends estimated from other studies (including CFAS I 
and II, and the Framingham study), and an alternative scenario in which dementia incidence does not 
decline any further (fig 6)
(Continued)
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 cardiovascular mortality in ELSA (see supplementary 
figure 4). Hence we used the annual percentage change 
in cardiovascular mortality to estimate temporal change 
in cardiovascular incidence. The calendar trend for cog-
nitive impairment or dementia was obtained from the 
joint model previously described. The effect of calendar 
time was imposed on the transition probabilities for 
2006 to obtain transition probabilities for future years.
The IMPACT-BAM model was implemented in R sta-
tistical software and a package specifically written for it 
by author PB. Stata-14 (StataCorp 2015. College Station, 
TX: StataCorp LP) was used for data management and 
regression analysis to derive model inputs. The R pack-
age “JM” was used for joint modelling of longitudinal 
and time to event data.
Assumptions and sensitivity analysis
Table 1  presents the underlying assumptions for 
IMPACT-BAM and the evidence supporting the assump-
tions. We conducted sensitivity analyses to address 
uncertainties in these assumptions. We considered four 
alternative scenarios for calendar trend in dementia 
incidence: calendar trend obtained from analysis on 
ELSA data; a 2% relative annual decline as inferred by 
the Framingham Heart Study18 ; a 1.1% relative annual 
decline as inferred by Cognitive Function and Ageing 
Study-I and Cognitive Function and Ageing Study-II13; 
and no calendar decline in dementia incidence. 
We  conducted a sensitivity analysis assuming the inci-
dence of cardiovascular disease will no longer decline 
and will remain stable after 2014.
To explore the impact of parameter uncertainty on 
model outputs, we conducted a probabilistic sensi-
tivity analysis using Monte Carlo simulation. The 
procedure entails sampling from specified distribu-
tions for the input parameters that were used in the 
model for each data cycle. We calculated 1000 itera-
tions to estimate 95% uncertainty intervals for out-
put variables.
Validation
To validate methods, definitions, and assumptions, we 
ran the model starting in 2006 to predict prevalence of 
dementia in 2011. We compared model estimates with 
the prevalence of dementia observed from the Cognitive 
Function and Ageing Study-II.20  Similarly, we compared 
the prevalence of cardiovascular disease with the 
health survey for England 2011,34 and mortality rates 
with data from the ONS. We also compared model pre-
dictions with dementia prevalence at wave 7 of ELSA.
Patient involvement
Study participants were not involved in setting the 
research question or the outcome measures, nor were 
they involved in developing plans for design or imple-
mentation of the study. No participants were asked to 
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Fig 2 | Projected number of people with dementia in 
england and Wales 2011-40. thinner lines represent 95% 
uncertainty intervals
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Fig 3 | age specific estimated number of cases of dementia 
2010-40 in men and women
table 1 | summary of assumptions underlying the iMPaCt-baM model
assumption justification
Assumption 13: Survival with cardiovascular disease, dementia, or 
functional impairment change over time in parallel to changes in 
overall life expectancy
Survival in IMPACT-BAM is indirectly modelled as a function of changing mortality rates. It is assumed 
that the ratio of mortality rates for each health state in the model compared with the general 
population is similar to that observed in ELSA. Thus mortality and survival for each health state in the 
model changes in parallel to mortality and survival in the general population. Current evidence 
suggests survival with cardiovascular disease and dementia is improving over time. We did not find 
evidence suggesting this improvement to be over and beyond improvement in overall survival
Assumption 14: The most likely net effect of future changes in risk 
factors will be the continuation of calendar trends in mortality rates 
and incidence of dementia and cardiovascular disease observed 
over the past two decades
Population levels of risk factors affecting incidence of cardiovascular disease and dementia such as 
diabetes, smoking, diet, and physical activity have changed over time. The net effect of recent changes 
in risk factors on changes in mortality rates and incidence of cardiovascular disease and dementia has 
been steady and linear declining calendar trends
The present analysis forms the baseline modelling scenario. IMPACT-BAM will be utilised in future to 
model the health impacts of changes in risk factors and public health interventions compared with the 
baseline scenario. Results of such analysis are extensive and beyond the scope of this paper
Competing risks
Assumption 15: Deaths due to any cause (including cancer and chronic 
obstructive pulmonary disease) and changes in cause specific 
mortality rates act as competing risks to development of dementia
Cardiovascular and non-cardiovascular causes of death are the terminal health states in the model. 
Once a person dies from any cause they are no longer at risk of disease. Thus, competing risks due to 
both cardiovascular and non-cardiovascular causes are accounted for in the model
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advise on interpretation or writing up of results. There 
are no direct plans to disseminate the results of the 
research to study participants.
results
Trends in dementia incidence: ELSA (2002-13)
Supplementary table 2 shows the baseline characteris-
tics of ELSA participants. Between 2002 and 2013 
dementia was ascertained for a total of 1448 ELSA 
 participants: 634 participants had dementia at the time 
of recruitment, and 814 incident cases were identified 
over the course of follow-up; 16.5% occurred in partici-
pants aged less than 65 years. Of the 1448 participants 
with dementia, 466 received a doctor diagnosis of 
dementia, 245 were identified through IQCODE ques-
tionnaire plus functional impairment in activities of 
daily living, and 1078 were identified by impairment in 
cognitive tests and impairment in one or more activities 
of daily living. Of the 245 participants with dementia 
based on IQCODE and functional impairment, 171 (70%) 
reported a doctor diagnosis of dementia. Among those 
with impairment in cognitive tests and activities of daily 
living function, 263 (25%) reported a doctor diagnosis of 
dementia at later stages or were considered to have 
dementia based on the IQCODE questionnaire.
Supplementary table 3 shows the number of incident 
dementia cases ascertained at each wave of data collec-
tion. Age-sex specific dementia incidence observed in 
ELSA was consistent with that observed in the indepen-
dent Cognitive Function and Ageing Study-II study, 
whereas incidence rates corrected for the effect of drop-
out were higher (see supplementary figure 5). Incidence 
rates of dementia corrected for the effect of dropout were 
higher at older ages, marginally higher in women than 
men (see supplementary figures 6 and 7.A), and higher 
than uncorrected crude observed rates (see supplemen-
tary figure 7.B). In 2015, age standardised incidence of 
dementia in the population of England and Wales aged 
50 or more years was estimated at 1.3% in men and 1.5% 
in women, corresponding to 125 800 new cases of 
dementia in men and 162 650 new cases in women.
The magnitude of the calendar trend in age specific 
dementia incidence, without correcting for either 
 mortality or selective dropout, was obtained from Cox 
proportional hazards analysis based on participants 
who attended and remained in the study at each two 
year interval. The age adjusted and sex adjusted demen-
tia incidence relatively decreased by 1.5% each year 
(hazard ratio 0.985, 95% confidence interval 0.954 to 
1.018; see supplementary figure 8.A). Accounting for the 
competing risk of mortality in separate competing risks 
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Fig 4 | Projected prevalence 
of dementia in england and 
Wales, 2011-40. thinner 
lines represent 95% 
uncertainty intervals
Fig 5 | Projected prevalence 
of dementia in england and 
Wales, 2011-40, age 
standardised to the 
population of 2015. thinner 
lines represent 95% 
uncertainty intervals
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analysis yielded a steeper trend of −2.7% (0.973, 0.932 to 
1.016). The effect of non-random dropout as well as 
changing mortality rates was accounted for by fitting 
joint models of longitudinal and time-to-event data. The 
corrected calendar trend in dementia incidence was a 
statistically significant relative reduction of 2.7% each 
year (odds ratio 0.973, 95% confidence interval 0.971 to 
0.976; see supplementary figures 6 and 8.B). The relative 
annual reduction tended to be steeper in women (0.972, 
0.968 to 0.976) than in men (0.975, 0.971 to 0.980), but 
the interaction by sex was not statistically significant. 
Changes over time in available risk factors accounted for 
about 25% of the calendar effect in dementia incidence 
(fully adjusted odds ratio 0.98 (95% confidence interval 
0.977 to 0.982); see supplementary table 4).
Trends in dementia prevalence: IMPACT-BAM
Age-sex specific prevalence of dementia at each data 
collection wave of ELSA provides the starting values for 
the IMPACT-BAM model (see supplementary table 5). In 
ELSA, age-sex standardised prevalence of dementia 
declined over time (see supplementary figure 9). For the 
purpose of validating the model, IMPACT-BAM was 
populated with age-sex specific prevalence estimates 
and transition probabilities for 2006 to estimate preva-
lence of dementia, cardiovascular disease, and mortal-
ity in 2011. The age-sex specific dementia prevalences 
predicted by IMPACT-BAM for 2011 (see supplementary 
figure 10) were compatible with estimates from the 
independent Cognitive Function and Ageing Study-II. 
Model predictions also matched prevalence of demen-
tia at wave 7 of ELSA (see supplementary figure 11). Car-
diovascular disease prevalence and mortality rates 
were compatible with observations from independent 
sources (see supplementary figures 12 and 13).
In the analyses on future prevalence of dementia up 
to 2040 assuming a 2.7% relative annual decline in 
dementia incidence, the number of people with demen-
tia in England and Wales is set to increase from 766 600 
(95% uncertainty interval 735 200 to 796 900) in 2016 to 
871 700 (835 600 to 906 600) in 2020, 1 091 600 (1 034 200 
to 1 146 200) in 2030, and 1 204 500 (1 101 000 to 
1 296 200) in 2040 (fig 2 ). Much of the increase in num-
ber of people with dementia occurs in the older age 
groups (fig 3 , see supplementary figure 14). Overall 
crude prevalence of dementia in the population aged 50 
or more is estimated at 3.5% (95% uncertainty interval 
3.4% to 3.7%) in 2016, 3.8% (3.7% to 4.0%) in 2020, 4.3% 
(4.1% to 4.5%) in 2030, and 4.4% (4.0% to 4.7%) in 2040 
(fig 4 ). The crude prevalence of dementia in population 
aged 50 or more and 65 or more is estimated to increase 
up to 2040 in men, whereas in women it declines after 
2025 (fig 4 ). These crude prevalence estimates are 
affected by the population structure. The prevalence 
of  dementia age standardised to the population of 
2015 is estimated to decline by about 21% from 2016 to 
2040 (fig 5).
Figure 6 shows the results of sensitivity analyses for 
predicted numbers of dementia cases based on differ-
ent values for calendar trend in dementia incidence. 
Assuming no calendar trend in dementia incidence, the 
number of people with dementia is estimated at 1.9 mil-
lion (95% uncertainty interval 1.76 million to 2.0 mil-
lion) in 2040, with an increase rather than a decrease in 
age standardised prevalence of dementia (see supple-
mentary figure 15). The predicted number of people 
with dementia under the assumption that cardiovascu-
lar disease incidence does not decline any further was 
758 700 (95% uncertainty interval 728 200 to 788 000) in 
2016 and 1 112 700 (1 023 400 to 1 192 700) in 2040 (see 
supplementary figure 16), 8% fewer compared with the 
scenario in which the incidence of cardiovascular dis-
ease continues to decline.
discussion
Our results shift the balance of evidence towards more 
certainty that dementia incidence is indeed decreasing. 
The decline, estimated at a relative reduction of 2.7% 
each year, was evident after accounting for mortality 
and non-random dropout from the study. Although age 
specific incidence of dementia is declining, the overall 
disease burden is set to increase substantially owing to 
increased life expectancy and declining rates of mortal-
ity and cardiovascular disease incidence. With current 
population projections, we estimate there will be a 57% 
increase in the number of people with dementia 
between 2016 and 2040, with more than 1.2 million peo-
ple with dementia in England and Wales by 2040.
strengths and limitations of this study
To our knowledge, this is the first study to predict num-
ber of cases and prevalence of dementia in a population 
using methods that simultaneously model the observed 
trends in mortality, cardiovascular disease, and demen-
tia. Previous predictions were based on constant age 
specific incidence6  or prevalence2  of dementia. An 
accurate projection of the number of people with 
dementia is only possible with a modelling strategy that 
accounts for the opposing effects of increasing life 
expectancy and declining dementia incidence, a 
requirement highlighted by the non-linearity of the gen-
erated estimates of prevalence in the present study. 
No calendar eect
1.1% relative annual reduction
2% relative annual reduction
2.7% relative annual reduction
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Fig 6 | sensitivity analysis for number of cases of dementia 
under alternative assumptions for calendar trend in 
incidence of dementia. thinner lines represent 95% 
uncertainty intervals
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On  the basis of the calendar effect derived from the 
English Longitudinal Study of Ageing (ELSA), there is 
an upward trend in numbers of people with dementia, 
but to a smaller degree than previously estimated. Pre-
vious forecasts of larger increases in dementia burden 
are based on less complex approaches that do not 
account for changes in dementia incidence, survival, or 
competing risks.4 35-37  Under the scenario of assuming 
that the incidence of dementia does not decline, preva-
lence projections for dementia were higher, and were 
similar to those of Alzheimer’s Society UK.2
Changes in mortality rates are important determi-
nants of the numbers of people with dementia as they 
govern both life expectancy and the pool of individuals 
susceptible to dementia, as well as survival in those 
affected by the condition,5  and thus are meticulously 
incorporated in the model. Cardiovascular and non-car-
diovascular mortality rates have shown steady and lin-
ear downward trends in the past decades, and we 
assumed this trend is likely to continue. IMPACT-BAM 
shows that the decline in age standardised dementia 
prevalence, corresponding to the decline in incidence, 
is outweighed by population aging in the near future, 
and numbers of people with dementia are likely to 
increase rapidly between 2015 and 2030. In the follow-
ing decade, however, the number of people with 
dementia will level out. Furthermore, the numbers of 
men and women with dementia is set to converge within 
the next 15 years. This finding can partly be explained 
by a faster decline in mortality rates in men compared 
with women (see supplementary figure 3) and narrow-
ing of the life expectancy gap between the sexes.9
We derived the required inputs for IMPACT-BAM from 
best available data. ELSA is a large, representative sam-
ple of the population aged 50 years or more and sur-
veyed using standard questions at two year intervals. 
Six waves of data allowed us to account for mortality 
and dropout from the study using robust statistical 
methods. Cognitive decline starts at a younger age38 
than the 65 or more or 70 or more age groups recruited 
in previous studies.12 13 18 24 39-41 We attempted to fill the 
gap by capturing cognitive impairment and dementia 
starting at age 50. Model outputs were validated against 
observations from independent sources.
ELSA participants were not clinically screened for 
dementia, rather, an operational case definition based 
on standardised assessments of cognition and function 
was applied. The standardised assessment is compara-
ble across time, and thus more informative of dementia 
trends than clinical assessments, which are likely to be 
affected by changes in diagnostic criteria21 22  and clini-
cal practice over time.23  The case definition applied in 
this study, follows DSM-IV and other clinical criteria 
(National Institute of Neurological Disorders and Stroke 
and the Association Internationale pour la Recherche et 
l’Enseignement en Neurosciences (NINDS-AIREN) and 
National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer’s Disease and 
Related Disorders Association (NINCDS-ADRDA)) in 
that it hinges on non-transient impairment in two or 
more cognitive domains, resulting in functional 
 impairment (see supplementary file, section 1). Cogni-
tive assessment in ELSA is based on a set of standard 
and validated30 42-45 cognitive function tests; none the 
less the list is not comprehensive. Cognitive impairment 
in domains other than those tested may have been 
missed, leading to underestimation of dementia cases. 
Similarity of age specific estimates of dementia inci-
dence and prevalence with those of CFAS-II suggests 
this source of bias is small.
The case definition for dementia used in this study 
required moderate to severe impairments in cognition and 
function to minimise false positives. This results in inclu-
sion of moderate to severe, rather than mild, cases of 
dementia. The main aim of this exercise is to inform future 
societal and healthcare needs. To this end, the dementia 
case definition is relevant to health and social policy as it 
forecasts numbers of people who would require support-
ive care owing to moderate or severe cognitive and func-
tional impairment. Although residents of care homes were 
not included in ELSA, we took account of this group using 
the statistical joint modelling approach. Furthermore, 
data from carers and self reported doctor diagnosis of 
dementia identified cases among those unable to take part 
in the study. Accounting for non-participation and drop-
out from the study increased the obtained incidence rates 
for dementia, but not by a considerable amount (see sup-
plementary figure 7), a finding consistent with the Mayo 
Clinic Study of Ageing.24
Survival with cardiovascular disease and dementia 
has improved over time.5 46 47  Changes in life expectancy 
and survival with cardiovascular disease, functional 
impairment, or dementia are accounted for in the model 
by applying calendar time specific mortality rates. This 
method is based on the assumption that survival with 
health conditions changes in proportion to changes in 
overall life expectancy. This assumption, although rea-
sonable and commonly applied in modelling stud-
ies,3 6 48  lacks verification, as evidence on the exact age 
and sex specific survival with dementia is rare,5 and it is 
hard to obtain given uncertainty over date of onset.
Comparison with other studies
Age specific and sex specific incidence rates of demen-
tia obtained using the described methods (before cor-
rection for dropouts) were in line with age-sex specific 
incidence rates obtained in other European studies, 
including the population of England (CFAS-II,13  see 
supplementary figure 3), Italy (Italian Longitudinal 
Study of Ageing),39  and Spain (NEDICES study),40 
higher than that in the Rotterdam study12  and relatively 
lower than American populations of Minnesota (Mayo 
Clinic Study of Ageing)24  and white participants of the 
Cardiovascular Health Study (1989-99).41 Although not 
suitable in a clinical setting, the similarity of our esti-
mates for age specific dementia incidence with those of 
independent studies underpins the validity of our case 
definition for dementia at population level.
Several cohorts and regionally representative panel 
studies have reported calendar trends in dementia 
 incidence.13 49  Comparing findings of CFAS I and II 
 studies13  showed a 20% decline in dementia incidence 
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over 20 years, statistically significant only in men, 
using algorithmic diagnosis among participants who 
attended reassessment interviews within two years of 
CFAS-I (1989-94) and CFAS-II (2008-11). Our results, 
based, in parallel, on participants who remained in the 
study at biennial waves of ELSA also translate to a 20% 
decline in dementia incidence over 20 years. After 
accounting for the competing effect of mortality and 
dropouts, the annual reduction was, as expected, larger 
(2.7%). This corresponds to a 42% decline in dementia 
incidence over two decades, and it is statistically 
 significant for both men and women. The corrected 
dementia trend, corresponding to a 24% decline for 
each decade, is consistent with findings from the Fram-
ingham study (20% decline for each decade across 1977-
2008),18  the Rotterdam study (non-statistically 
significant 25% lower incidence in the 2000 compared 
with the 1990 subcohort),12  and the Chicago Health and 
Aging project (non-significant 3% annual reduction 
across 1997-2008).14  Other studies suggested a decline 
in dementia incidence, indirectly inferred from compar-
ing prevalence estimates in Spain50  and Sweden.15 
Some studies in the United States,14  China,51  and 
Japan52  found no statistically significant trend. No pub-
lished study has reported evidence of an increasing 
trend in dementia incidence.49
Several plausible explanations support a decline in 
dementia incidence over time. Improvement in vascular 
risk factors,7 8 53 as well as in education levels, can partly 
account for the decline in incidence. In the present 
study, increased physical activity accounted for the 
largest proportion of the decline in dementia incidence 
between 2002 and 2013. Changes in prevalence of dia-
betes, smoking, and social class over time had negative 
confounding effects, such that the downward incidence 
trend increased after controlling for respective changes. 
Adjustment for stroke and depression did not have a 
considerable effect on the calendar trend in dementia.
Policy implications
Basic research efforts to understand the causes of 
dementia have increased noticeably in recent years, but 
to date drug trials have failed to show modification of 
disease processes.54  The WHO and other expert bodies 
have identified prevention, identification, and reduc-
tion of risk as a top research priority, in response to the 
lack of treatment.55 56 Debate continues about the rela-
tive importance of vascular and neurodegenerative 
causes. In the context of this uncertainty the IMPACT-
BAM model is a means to understand how the dementia 
burden will evolve, and it provides a platform to mea-
sure how the burden might be reduced through various 
policy interventions.
Conclusion
Our novel prediction model integrates recent downward 
trends in dementia and cardiovascular disease inci-
dence with declining mortality rates in England and 
Wales. If these trends continue then the number of peo-
ple with dementia will more than likely increase, from 
792 000 in 2017 to more than 1.2 million in 2040. The pro-
jected increase in the burden of dementia, despite the 
substantial downward trend in age specific incidence, 
results largely from improvements in life expectancy. 
The results have important policy implications in terms 
of care needs and public spending. The findings of our 
prediction model act as a benchmark to measure the 
impact of possible dementia prevention initiatives.
We thank all ELSA study participants and the study team for their 
contribution, Panayotes Demakakos for help with use of the ELSA 
dataset, and Dimitris Rizopoulos for statistical help.
Contributors: All authors made substantial contribution to the 
conception and design of this study. EJB and MOF developed the 
original idea for IMPACT-BAM. SAA, MJS, MGC, and PB analysed and 
prepared the input data for the model. PB and MGC developed and 
implemented the model, with input from MOF, SAA, MJS, EJB, and SC. 
SAA ran the joint model of longitudinal and time to event data, with 
input from MJS and GMT. SAA wrote the manuscript with coauthors. All 
authors contributed to interpreting the results, drafting the 
manuscript, and the revisions. SAA and EJB are the guarantors.
Funding: This study was funded by grants from the British Heart 
Foundation (RG/13/2/30098, RG/16/11/32334). MK was supported 
by the Medical Research Council (K013351) and NordForsk. The 
funding sources did not have a role in the design and conduct of the 
study, the collection, management, analysis, and interpretation of the 
data, or the preparation, review, approval, or decision to submit the 
manuscript.
Competing interests: All authors have completed the ICMJE uniform 
disclosure form at www.icmje.org/coi_disclosure.pdf and declare no 
support from any organisation for the submitted work; no financial 
relationships with any organisations that might have an interest in the 
submitted work in the previous three years; no other relationships or 
activities that could appear to have influenced the submitted work.
Ethical approval: This study was approved by the multicenter 
research and ethics committee.
Data sharing: Technical appendix with details on the formula and 
calculations for the IMPACT-BAM model is available from the 
corresponding author.
Transparency: The lead author (SAA) affirms that the manuscript is an 
honest, accurate, and transparent account of the study being reported; 
that no important aspects of the study have been omitted; and that 
any discrepancies from the study as planned have been explained.
This is an Open Access article distributed in accordance with the terms 
of the Creative Commons Attribution (CC BY 4.0) license, which 
permits others to distribute, remix, adapt and build upon this work, for 
commercial use, provided the original work is properly cited. See: 
http://creativecommons.org/licenses/by/4.0/.
1 World Alzheimer report 2015. The global impact of dementia, an 
analysis of prevalence, incidence, cost and trends. 2015. 
Alzheimer’s Disease International.
2 Dementia UK. A report into the prevalence and cost of dementia 
prepared by the Personal Social Services Unit (PSSRU) at the London 
School of Economics and the Institute of Psychiatry at King’s College 
London, for the Alzheimer’s society.Alzheimer's Society, 2007.
3 Murray CJ, Richards MA, Newton JN, et al. UK health performance: 
findings of the Global Burden of Disease Study 2010. Lancet 
2013;381:997-1020. doi:10.1016/S0140-6736(13)60355-4. 
4 Norton S, Matthews FE, Brayne C. A commentary on studies 
presenting projections of the future prevalence of dementia. BMC 
Public Health 2013;13:1. doi:10.1186/1471-2458-13-1. 
5 Prince M, Ali GC, Guerchet M, Prina AM, Albanese E, Wu YT. Recent 
global trends in the prevalence and incidence of dementia, and 
survival with dementia. Alzheimers Res Ther 2016;8:23-0188. 
doi:10.1186/s13195-016-0188-8. 
6 Wanneveich M, Jacqmin-Gadda H, Dartigues JF, Joly P. Impact of 
intervention targeting risk factors on chronic disease burden. Stat 
Methods Med Res 2016;Mar 17:0962280216631360.
7 Barnes DE, Yaffe K. The projected effect of risk factor reduction on 
Alzheimer’s disease prevalence. Lancet Neurol 2011;10:819-28. 
doi:10.1016/S1474-4422(11)70072-2. 
8 Brunner EJ, Welch CA, Shipley MJ, Ahmadi-Abhari S, Singh-Manoux A, 
Kivimaki M. Midlife risk factors for impaired physical and cognitive 
functioning at older ages: a cohort study. J Gerontol A Biol Sci Med Sci 
2017;72:237-42.
9 Bennett JE, Li G, Foreman K, et al. The future of life expectancy and life 
expectancy inequalities in England and Wales: Bayesian 
spatiotemporal forecasting. Lancet 2015;386:163-70. doi:10.1016/
S0140-6736(15)60296-3. 
RESEARCH
See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
10 NICE guideline. Dementia, disability and frailty in later life: mid-life 
approaches to delay or prevent onset. 20-10-2015.
11 Lincoln P, Fenton K, Alessi C, et al. The Blackfriars Consensus on brain 
health and dementia. Lancet 2014;383:1805-6. doi:10.1016/
S0140-6736(14)60758-3. 
12 Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, 
Breteler MM. Is dementia incidence declining?: Trends in dementia 
incidence since 1990 in the Rotterdam Study. Neurology 
2012;78:1456-63. doi:10.1212/WNL.0b013e3182553be6. 
13 Matthews FE, Stephan BC, Robinson L, et al. Cognitive Function and 
Ageing Studies (CFAS) Collaboration. A two decade dementia incidence 
comparison from the Cognitive Function and Ageing Studies I and II. 
Nat Commun 2016;7:11398. doi:10.1038/ncomms11398. 
14 Rocca WA, Petersen RC, Knopman DS, et al. Trends in the incidence 
and prevalence of Alzheimer’s disease, dementia, and cognitive 
impairment in the United States. Alzheimers Dement 2011;7:80-93. 
doi:10.1016/j.jalz.2010.11.002. 
15 Qiu C, von Strauss E, Bäckman L, Winblad B, Fratiglioni L. Twenty-year 
changes in dementia occurrence suggest decreasing incidence in 
central Stockholm, Sweden. Neurology 2013;80:1888-94. 
doi:10.1212/WNL.0b013e318292a2f9. 
16 Doblhammer G, Fink A, Zylla S, Willekens F. Compression or expansion 
of dementia in Germany? An observational study of short-term trends 
in incidence and death rates of dementia between 2006/07 and 
2009/10 based on German health insurance data. Alzheimers Res 
Ther 2015;7:66-0146. doi:10.1186/s13195-015-0146-x. 
17 Grasset L, Brayne C, Joly P, et al. Trends in dementia incidence: 
Evolution over a 10-year period in France. Alzheimers Dement 
2016;12:272-80. doi:10.1016/j.jalz.2015.11.001. 
18 Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. 
Incidence of Dementia over Three Decades in the Framingham Heart 
Study. N Engl J Med 2016;374:523-32. doi:10.1056/NEJMoa1504327. 
19 Prince M, Ferri CP, Acosta D, et alThe protocols for the 10/66 dementia 
research group population-based research programme. BMC Public 
Health 2007;7:165.
20 Matthews FE, Arthur A, Barnes LE, et al. Medical Research Council 
Cognitive Function and Ageing Collaboration. A two-decade 
comparison of prevalence of dementia in individuals aged 65 years 
and older from three geographical areas of England: results of the 
Cognitive Function and Ageing Study I and II. Lancet 2013;382:1405-
12. doi:10.1016/S0140-6736(13)61570-6. 
21 Langa KM, Larson EB, Karlawish JH, et al. Trends in the prevalence and 
mortality of cognitive impairment in the United States: is there 
evidence of a compression of cognitive morbidity?Alzheimers Dement 
2008;4:134-44. doi:10.1016/j.jalz.2008.01.001. 
22 Prince MJ, de Rodriguez JL, Noriega L, et al. 10/66 Dementia research group. 
The 10/66 Dementia Research Group’s fully operationalised DSM-IV 
dementia computerized diagnostic algorithm, compared with the 10/66 
dementia algorithm and a clinician diagnosis: a population validation 
study. BMC Public Health 2008;8:219. doi:10.1186/1471-2458-8-219. 
23 Baldereschi M, Amato MP, Nencini P, et al. Cross-national interrater 
agreement on the clinical diagnostic criteria for dementia. WHO-PRA 
Age-Associated Dementia Working Group, WHO-Program for Research 
on Aging, Health of Elderly Program. Neurology 1994;44:239-42. 
doi:10.1212/WNL.44.2.239. 
24 Knopman DS, Roberts RO, Pankratz VS, et al. Incidence of dementia among 
participants and nonparticipants in a longitudinal study of cognitive aging. 
Am J Epidemiol 2014;180:414-23. doi:10.1093/aje/kwu103. 
25 Binder N, Schumacher M, Joly P. Re: “Incidence of dementia among 
participants and nonparticipants in a longitudinal study of cognitive 
aging”. Am J Epidemiol 2015;181:291-2. doi:10.1093/aje/kwu475. 
26 Rizopoulos D. Joint models for longitudinal and time-to-event data, with 
applications in R.Chapman and Hall / CRC press, 2012doi:10.1201/b12208.
27 Steptoe A, Breeze E, Banks J, Nazroo J. Cohort profile: the English 
longitudinal study of ageing. Int J Epidemiol 2013;42:1640-8. 
doi:10.1093/ije/dys168. 
28 Mindell J, Biddulph JP, Hirani V, et al. Cohort profile: the health survey 
for England. Int J Epidemiol 2012;41:1585-93. doi:10.1093/ije/dyr199. 
29 Harrison JK, Fearon P, Noel-Storr AH, McShane R, Stott DJ, Quinn TJ. 
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) 
for the diagnosis of dementia within a secondary care setting. 
Cochrane Database Syst Rev 2015;3:CD010772. 
doi:10.1002/14651858.CD010772.pub2.:CD010772. 
30 Chertkow H, Nasreddine Z, Joanette Y, et al. Mild cognitive impairment 
and cognitive impairment, no dementia: Part A, concept and diagnosis. 
Alzheimers Dement 2007;3:266-82. doi:10.1016/j.jalz.2007.07.013. 
31 Haller B, Schmidt G, Ulm K. Applying competing risks regression 
models: an overview. Lifetime Data Anal 2013;19:33-58. doi:10.1007/
s10985-012-9230-8. 
32 Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach 
AD. A note on competing risks in survival data analysis. Br J Cancer 
2004;91:1229-35. doi:10.1038/sj.bjc.6602102. 
33 Guzman Castillo M, Gillespie DO, Allen K, et al. Future declines of 
coronary heart disease mortality in England and Wales could counter 
the burden of population ageing. PLoS One 2014;9:e99482. 
doi:10.1371/journal.pone.0099482. 
34 Health Survey for England 2011. 20-12-2012. Health and social care 
information centre.
35 Nepal B, Brown L, Ranmuthugala G. Modelling the impact of 
modifying lifestyle risk factors on dementia prevalence in Australian 
population aged 45 years and over, 2006-2051. Australas J Ageing 
2010;29:111-6. doi:10.1111/j.1741-6612.2010.00392.x. 
36 Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the 
United States (2010-2050) estimated using the 2010 census. 
Neurology 2013;80:1778-83. doi:10.1212/WNL.0b013e31828726f5. 
37 Comas-Herrera A, Wittenberg R, Pickard L, Knapp M. Cognitive 
impairment in older people: future demand for long-term care 
services and the associated costs. Int J Geriatr Psychiatry 
2007;22:1037-45. doi:10.1002/gps.1830. 
38 Singh-Manoux A, Kivimaki M, Glymour MM, et al. Timing of onset of 
cognitive decline: results from Whitehall II prospective cohort study. 
BMJ 2012;344:d7622. doi:10.1136/bmj.d7622. 
39 Noale M, Limongi F, Zambon S, Crepaldi G, Maggi S. ILSA Working 
Group. Incidence of dementia: evidence for an effect modification by 
gender. The ILSA Study. Int Psychogeriatr 2013;25:1867-76. 
doi:10.1017/S1041610213001300. 
40 Bermejo-Pareja F, Benito-León J, Vega S, Medrano MJ, Román GC. 
Neurological Disorders in Central Spain (NEDICES) Study Group. 
Incidence and subtypes of dementia in three elderly populations of 
central Spain. J Neurol Sci 2008;264:63-72. doi:10.1016/j.
jns.2007.07.021. 
41 Fitzpatrick AL, Kuller LH, Ives DG, et al. Incidence and prevalence of 
dementia in the Cardiovascular Health Study. J Am Geriatr Soc 
2004;52:195-204. doi:10.1111/j.1532-5415.2004.52058.x. 
42 Stephan BC, Kurth T, Matthews FE, Brayne C, Dufouil C. Dementia risk 
prediction in the population: are screening models accurate?Nat Rev 
Neurol 2010;6:318-26. doi:10.1038/nrneurol.2010.54. 
43 Lonie JA, Tierney KM, Ebmeier KP. Screening for mild cognitive 
impairment: a systematic review. Int J Geriatr Psychiatry 2009;24:902-
15. doi:10.1002/gps.2208. 
44 Masur DM, Sliwinski M, Lipton RB, Blau AD, Crystal HA. 
Neuropsychological prediction of dementia and the absence of 
dementia in healthy elderly persons. Neurology 1994;44:1427-32. 
doi:10.1212/WNL.44.8.1427. 
45 Welsh KA, Butters N, Hughes JP, Mohs RC, Heyman A. Detection and 
staging of dementia in Alzheimer’s disease. Use of the 
neuropsychological measures developed for the Consortium to 
Establish a Registry for Alzheimer’s Disease. Arch Neurol 
1992;49:448-52. doi:10.1001/archneur.1992.00530290030008. 
46 Mendoza W, Miranda JJ. Global Shifts in Cardiovascular Disease, the 
Epidemiologic Transition, and Other Contributing Factors: Toward a 
New Practice of Global Health Cardiology. Cardiol Clin 2017;35:1-12. 
doi:10.1016/j.ccl.2016.08.004. 
47  GBD 2013 Mortality and Causes of Death Collaborators. Global, 
regional, and national age-sex specific all-cause and cause-specific 
mortality for 240 causes of death, 1990-2013: a systematic analysis 
for the Global Burden of Disease Study 2013. Lancet 2015;385:117-71. 
doi:10.1016/S0140-6736(14)61682-2. 
48 Lewis FI, Torgerson PR. The current and future burden of late-onset 
dementia in the United Kingdom: Estimates and interventions. 
Alzheimers Dement 2017;13:38-44. doi:10.1016/j.jalz.2016.03.013. 
49 Wu YT, Fratiglioni L, Matthews FE, et al. Dementia in western Europe: 
epidemiological evidence and implications for policy making. Lancet 
Neurol 2015;15:10-4422.
50 Lobo A, Saz P, Marcos G, et al. ZARADEMP Workgroup. Prevalence of 
dementia in a southern European population in two different time 
periods: the ZARADEMP Project. Acta Psychiatr Scand 2007;116:299-
307. doi:10.1111/j.1600-0447.2007.01006.x. 
51 Wu YT, Lee HY, Norton S, et al. Period, birth cohort and prevalence of 
dementia in mainland China, Hong Kong and Taiwan: a meta-analysis. 
Int J Geriatr Psychiatry 2014;29:1212-20. doi:10.1002/gps.4148. 
52 Sekita A, Ninomiya T, Tanizaki Y, et al. Trends in prevalence of 
Alzheimer’s disease and vascular dementia in a Japanese community: 
the Hisayama Study. Acta Psychiatr Scand 2010;122:319-25. 
doi:10.1111/j.1600-0447.2010.01587.x. 
53 Hardoon SL, Morris RW, Whincup PH, et al. Rising adiposity curbing 
decline in the incidence of myocardial infarction: 20-year follow-up of 
British men and women in the Whitehall II cohort. Eur Heart J 
2012;33:478-85. doi:10.1093/eurheartj/ehr142. 
54 Gauthier S, Albert M, Fox N, et al. Why has therapy development for 
dementia failed in the last two decades?Alzheimers Dement 
2016;12:60-4. doi:10.1016/j.jalz.2015.12.003. 
55 Shah H, Albanese E, Duggan C, et al. Research priorities to reduce the 
global burden of dementia by 2025. Lancet Neurol 2016;15:1285-94. 
doi:10.1016/S1474-4422(16)30235-6. 
56 Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease 
and other dementias: a priority for European science and society. 
Lancet Neurol 2016;15:455-532. doi:10.1016/
S1474-4422(16)00062-4. 
Supplementary information: additional material
